UF Innovate Tech Licensing

Targeting tumors without harming healthy tissue remains one of oncology’s biggest challenges. 🩺

Led by Dr. Christoph Rader from Scripps Research and The Wertheim UF Scripps Institute, rresearchers have developed high-affinity anti-ROR2 antibodies that selectively bind ROR2-positive tumors. The platform supports monoclonal antibodies, antibody-drug conjugates, and T-cell engagers for targeted cancer therapies.

By focusing on the tumor-associated ROR2 receptor with high specificity, the technology could support more precise targeting while reducing off-target risk. This University of Florida innovation supports the development of safer therapeutics, diagnostics, and imaging tools for precision oncology.

Learn more about this tech now: https://ufinnovate.technologypublisher.com/techcase/MP26055